⌕
Ascendis Pharma · ASND · Nasdaq
Tenet 53 · Mixed
Compare
$271.19−0.20%At closeTenet 53 · Mixed
$271.19−0.54 (−0.20%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ascendis Pharma (ASND) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ASND's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 09:22 ET
Ascendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Ascendis Pharma A/S (ASND) Jefferies Global Healthcare Conference 2026 November 17, 2026 6:30 AM EST Company Participants Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, …

ASND −0.2% todayRead at source ↗
● MarketBeatNov 12, 2026 · 12:17 ET
Ascendis Pharma A/S Q3 Earnings Call Highlights

Ascendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL…

ASND −0.2% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 11:59 ET
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Ascendis Pharma Reports Third Quarter 2026 Financial Results

Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing …

ASND −0.2% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference

COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesd…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 08:00 ET
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union

– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products (COM…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12, 20…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireOct 26, 2026 · 08:00 ET
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with …

ASND −0.2% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 08:29 ET
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted …

ASND −0.2% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 09:15 ETCOMPANY'S OWN WORDS
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026…

ASND −0.2% todayRead at source ↗
● Defense WorldSep 28, 2026 · 08:07 ET
Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They presently have a…

ASND −0.2% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 15:02 ET
Ascendis Pharma: Back To Full Independence

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and …

ASND −0.2% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 18:01 ET
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ASND −0.2% todayRead at source ↗
● BenzingaSep 15, 2026 · 13:56 ET
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireSep 14, 2026 · 18:00 ETCOMPANY'S OWN WORDS
Ascendis Announces Planned $400 Million Share Repurchase Program

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireSep 14, 2026 · 18:00 ETCOMPANY'S OWN WORDS
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and c…

ASND −0.2% todayRead at source ↗
● Defense WorldSep 11, 2026 · 03:45 ET
Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the streng…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 16:01 ET
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 16:01 ET
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare C…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireSep 7, 2026 · 07:00 ET
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress …

ASND −0.2% todayRead at source ↗
● BenzingaAug 31, 2026 · 10:30 ET
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.…

ASND −0.2% todayRead at source ↗
● BenzingaAug 31, 2026 · 08:06 ET
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.…

ASND −0.2% todayRead at source ↗
● GlobeNewsWireAug 31, 2026 · 07:00 ET
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutica…

ASND −0.2% todayRead at source ↗
● BenzingaAug 27, 2026 · 10:52 ET
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

ASND −0.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just ASND · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.